Chang Ho Kim Selected Research

TP protocol

1/2020	Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
3/2016	A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
1/2016	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
11/2013	Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chang Ho Kim Research Topics

Disease

30	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2002
26	Neoplasms (Cancer) 01/2021 - 01/2002
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2011
11	Pleural Effusion (Pleural Effusions) 02/2022 - 10/2015
5	Infections 02/2022 - 04/2013
5	Adenocarcinoma of Lung 01/2022 - 08/2010
5	Respiratory Insufficiency (Respiratory Failure) 05/2018 - 03/2007
5	Tuberculosis (Tuberculoses) 05/2015 - 12/2008
4	Malignant Pleural Effusion 01/2022 - 01/2016
4	Neoplasm Metastasis (Metastasis) 01/2015 - 10/2011
3	Adenocarcinoma 01/2020 - 10/2003
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 01/2002
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 10/2003
3	Carcinogenesis 04/2014 - 01/2006
3	Genetic Predisposition to Disease (Genetic Predisposition) 04/2008 - 10/2003
3	Ischemia 08/2006 - 01/2005
2	Schmid-Fraccaro syndrome 07/2021 - 01/2017
2	Pneumonia (Pneumonitis) 05/2019 - 01/2013
2	Miliary Tuberculosis 05/2018 - 04/2014
2	Hypoalbuminemia 04/2013 - 04/2011
2	Lymphopenia (Lymphocytopenia) 04/2013 - 04/2011
2	Cryptogenic Organizing Pneumonia 01/2013 - 01/2011
2	Chronic Obstructive Pulmonary Disease (COPD) 12/2012 - 09/2008
2	Pulmonary Tuberculosis 07/2012 - 04/2011
2	Colorectal Neoplasms (Colorectal Cancer) 02/2012 - 10/2011
1	Venous Thromboembolism 04/2022
1	Dehydration (Water Stress) 04/2022
1	Pulmonary Embolism 04/2022
1	Lymphatic Metastasis 01/2021
1	Lymphoma (Lymphomas) 08/2019
1	Chronic Cough 05/2019
1	Chronic Disease (Chronic Diseases) 05/2018
1	Lipid Pneumonia 04/2018
1	Neuroendocrine Carcinoma 01/2015
1	Teratoma (Teratoid Tumor) 01/2015
1	Fistula 11/2014
1	Dyspnea (Shortness of Breath) 06/2014
1	Genomic Instability 04/2014

Drug/Important Bio-Agent (IBA)

9	Adenosine DeaminaseIBA 02/2022 - 10/2015
7	Messenger RNA (mRNA)IBA 01/2020 - 10/2011
6	MicroRNAs (MicroRNA)IBA 01/2021 - 10/2010
5	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2007
5	SmokeIBA 08/2010 - 01/2002
4	CytokinesIBA 01/2020 - 04/2013
4	Proteins (Proteins, Gene)FDA Link 11/2014 - 01/2005
3	C-Reactive ProteinIBA 01/2017 - 04/2011
3	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 01/2008
3	InterferonsIBA 07/2014 - 04/2013
3	Codon (Codons)IBA 10/2003 - 01/2002
2	Anaplastic Lymphoma KinaseIBA 01/2022 - 02/2012
2	ChemokinesIBA 07/2021 - 01/2020
2	dinophysistoxin 1IBA 01/2020 - 10/2019
2	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 06/2019 - 10/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2016 - 03/2005
2	Co-Repressor ProteinsIBA 10/2016 - 11/2014
2	GoldIBA 05/2015 - 04/2014
2	Telomerase (Telomerase Reverse Transcriptase)IBA 04/2014 - 01/2011
2	Interferon-gamma (Interferon, gamma)IBA 07/2012 - 04/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2011 - 09/2010
2	SteroidsIBA 01/2011 - 03/2007
2	Caspase 3 (Caspase-3)IBA 08/2010 - 05/2008
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2007 - 08/2006
1	Pharmaceutical PreparationsIBA 04/2022
1	CreatineIBA 04/2022
1	Immunoglobulin M (IgM)IBA 02/2022
1	Small Interfering RNA (siRNA)IBA 01/2022
1	alectinibIBA 01/2022
1	Histones (Histone)IBA 11/2021
1	Butyrates (Butyrate)IBA 07/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Activating Transcription Factor 3IBA 01/2021
1	6- trimethylsilylthio- 9- trimethylsilylpurineIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Carcinoembryonic AntigenIBA 01/2020
1	CarbonIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2019
1	AlbuminsIBA 05/2018
1	Hemoglobins (Hemoglobin)IBA 05/2018
1	LipidsIBA 04/2018
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2017
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 10/2016
1	AntigensIBA 05/2015
1	Biomarkers (Surrogate Marker)IBA 05/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2015
1	Macrophage Colony-Stimulating FactorIBA 11/2014
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2014
1	Bevacizumab (Avastin)FDA Link 02/2014
1	AcidsIBA 04/2013
1	Immunomodulating AgentsIBA 01/2013

Therapy/Procedure

9	Drug Therapy (Chemotherapy) 01/2020 - 03/2006
4	TP protocol 01/2020 - 11/2013
2	Ligation 01/2021 - 03/2016
2	Therapeutics 07/2014 - 07/2013
2	Artificial Respiration (Mechanical Ventilation) 12/2008 - 03/2007
1	Renal Dialysis (Hemodialysis) 01/2022
1	Adjuvant Chemotherapy 01/2021
1	Aftercare (After-Treatment) 05/2015
1	Laparoscopic Cholecystectomy 11/2014
1	Length of Stay 06/2014